Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Development of an oral reference dose for the perfluorinated compound GenX.

Thompson CM, Fitch SE, Ring C, Rish W, Cullen JM, Haws LC.

J Appl Toxicol. 2019 Sep;39(9):1267-1282. doi: 10.1002/jat.3812. Epub 2019 Jun 18.

2.
3.

Comparison of Toxicity and Recovery in the Duodenum of B6C3F1 Mice Following Treatment with Intestinal Carcinogens Captan, Folpet, and Hexavalent Chromium.

Thompson CM, Wolf JC, McCoy A, Suh M, Proctor DM, Kirman CR, Haws LC, Harris MA.

Toxicol Pathol. 2017 Dec;45(8):1091-1101. doi: 10.1177/0192623317742324. Epub 2017 Nov 21.

4.

Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium.

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA.

J Appl Toxicol. 2018 Mar;38(3):351-365. doi: 10.1002/jat.3545. Epub 2017 Oct 24.

5.

Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents.

Thompson CM, Suh M, Proctor DM, Haws LC, Harris MA.

Mutat Res. 2017 Nov;823:45-57. doi: 10.1016/j.mrgentox.2017.08.004. Epub 2017 Sep 12. Review.

6.

High-Throughput Screening Data Interpretation in the Context of In Vivo Transcriptomic Responses to Oral Cr(VI) Exposure.

Rager JE, Ring CL, Fry RC, Suh M, Proctor DM, Haws LC, Harris MA, Thompson CM.

Toxicol Sci. 2017 Jul 1;158(1):199-212. doi: 10.1093/toxsci/kfx085.

7.

Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA.

Environ Mol Mutagen. 2016 Dec;57(9):706-716. doi: 10.1002/em.22064. Epub 2016 Nov 15.

8.

Reduction of hexavalent chromium by fasted and fed human gastric fluid. II. Ex vivo gastric reduction modeling.

Kirman CR, Suh M, Hays SM, Gürleyük H, Gerads R, De Flora S, Parker W, Lin S, Haws LC, Harris MA, Proctor DM.

Toxicol Appl Pharmacol. 2016 Sep 1;306:120-33. doi: 10.1016/j.taap.2016.07.002. Epub 2016 Jul 7.

9.

Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA.

Mutat Res Genet Toxicol Environ Mutagen. 2016 Apr;800-801:28-34. doi: 10.1016/j.mrgentox.2016.01.008. Epub 2016 Mar 6.

10.

A high dose mode of action for tetrabromobisphenol A-induced uterine adenocarcinomas in Wistar Han rats: A critical evaluation of key events in an adverse outcome pathway framework.

Wikoff DS, Rager JE, Haws LC, Borghoff SJ.

Regul Toxicol Pharmacol. 2016 Jun;77:143-59. doi: 10.1016/j.yrtph.2016.01.018. Epub 2016 Jan 28. Review.

11.

Duodenal crypt health following exposure to Cr(VI): Micronucleus scoring, γ-H2AX immunostaining, and synchrotron X-ray fluorescence microscopy.

Thompson CM, Wolf JC, Elbekai RH, Paranjpe MG, Seiter JM, Chappell MA, Tappero RV, Suh M, Proctor DM, Bichteler A, Haws LC, Harris MA.

Mutat Res Genet Toxicol Environ Mutagen. 2015 Aug;789-790:61-6. doi: 10.1016/j.mrgentox.2015.05.004. Epub 2015 May 14.

12.

Development of toxicity values and exposure estimates for tetrabromobisphenol A: application in a margin of exposure assessment.

Wikoff D, Thompson C, Perry C, White M, Borghoff S, Fitzgerald L, Haws LC.

J Appl Toxicol. 2015 Nov;35(11):1292-308. doi: 10.1002/jat.3132. Epub 2015 Mar 30.

13.

Synchrotron-based imaging of chromium and γ-H2AX immunostaining in the duodenum following repeated exposure to Cr(VI) in drinking water.

Thompson CM, Seiter J, Chappell MA, Tappero RV, Proctor DM, Suh M, Wolf JC, Haws LC, Vitale R, Mittal L, Kirman CR, Hays SM, Harris MA.

Toxicol Sci. 2015 Jan;143(1):16-25. doi: 10.1093/toxsci/kfu206. Epub 2014 Oct 28.

14.

High concentrations of hexavalent chromium in drinking water alter iron homeostasis in F344 rats and B6C3F1 mice.

Suh M, Thompson CM, Kirman CR, Carakostas MC, Haws LC, Harris MA, Proctor DM.

Food Chem Toxicol. 2014 Mar;65:381-8. doi: 10.1016/j.fct.2014.01.009. Epub 2014 Jan 10.

15.

Evaluation of impact of shale gas operations in the Barnett Shale region on volatile organic compounds in air and potential human health risks.

Bunch AG, Perry CS, Abraham L, Wikoff DS, Tachovsky JA, Hixon JG, Urban JD, Harris MA, Haws LC.

Sci Total Environ. 2014 Jan 15;468-469:832-42. doi: 10.1016/j.scitotenv.2013.08.080. Epub 2013 Sep 25. Erratum in: Sci Total Environ. 2014 Jul 15;487:574.

16.

A review of background dioxin concentrations in urban/suburban and rural soils across the United States: implications for site assessments and the establishment of soil cleanup levels.

Urban JD, Wikoff DS, Bunch AT, Harris MA, Haws LC.

Sci Total Environ. 2014 Jan 1;466-467:586-97. doi: 10.1016/j.scitotenv.2013.07.065. Epub 2013 Aug 15. Review.

PMID:
23955251
17.

A chronic oral reference dose for hexavalent chromium-induced intestinal cancer.

Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays SM, Hixon JG, Harris MA.

J Appl Toxicol. 2014 May;34(5):525-36. doi: 10.1002/jat.2907. Epub 2013 Aug 14.

18.

Physiologically based pharmacokinetic model for humans orally exposed to chromium.

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, Parker W, Hays SM.

Chem Biol Interact. 2013 Jun 25;204(1):13-27. doi: 10.1016/j.cbi.2013.04.003. Epub 2013 Apr 17.

19.

Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water.

O'Brien TJ, Ding H, Suh M, Thompson CM, Parsons BL, Harris MA, Winkelman WA, Wolf JC, Hixon JG, Schwartz AM, Myers MB, Haws LC, Proctor DM.

Mutat Res. 2013 Jun 14;754(1-2):15-21. doi: 10.1016/j.mrgentox.2013.03.008. Epub 2013 Apr 9.

20.

The importance of problem formulations in risk assessment: a case study involving dioxin-contaminated soil.

Dourson ML, Gadagbui B, Griffin S, Garabrant DH, Haws LC, Kirman C, Tohyama C.

Regul Toxicol Pharmacol. 2013 Jul;66(2):208-16. doi: 10.1016/j.yrtph.2013.03.010. Epub 2013 Mar 29.

21.

Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans.

Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA.

Crit Rev Toxicol. 2013 Mar;43(3):244-74. doi: 10.3109/10408444.2013.768596. Review.

22.

Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium.

Kirman CR, Hays SM, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM.

Chem Biol Interact. 2012 Oct 25;200(1):45-64. doi: 10.1016/j.cbi.2012.08.016. Epub 2012 Sep 6. Erratum in: Chem Biol Interact. 2013 Aug 25;204(3):201-6.

23.

Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling.

Thompson CM, Gaylor DW, Tachovsky JA, Perry C, Carakostas MC, Haws LC.

J Appl Toxicol. 2013 Dec;33(12):1395-406. doi: 10.1002/jat.2799. Epub 2012 Aug 31.

PMID:
22936336
24.

Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis.

Thompson CM, Fedorov Y, Brown DD, Suh M, Proctor DM, Kuriakose L, Haws LC, Harris MA.

PLoS One. 2012;7(8):e42720. doi: 10.1371/journal.pone.0042720. Epub 2012 Aug 8.

25.

Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: an in silico comparison with mutagenic and nonmutagenic carcinogens across tissues.

Thompson CM, Gregory Hixon J, Proctor DM, Haws LC, Suh M, Urban JD, Harris MA.

Regul Toxicol Pharmacol. 2012 Oct;64(1):68-76. doi: 10.1016/j.yrtph.2012.05.019. Epub 2012 Jun 15.

26.

Hexavalent chromium reduction kinetics in rodent stomach contents.

Proctor DM, Suh M, Aylward LL, Kirman CR, Harris MA, Thompson CM, Gürleyük H, Gerads R, Haws LC, Hays SM.

Chemosphere. 2012 Oct;89(5):487-93. doi: 10.1016/j.chemosphere.2012.04.065. Epub 2012 Jun 8.

27.

Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90days of exposure to hexavalent chromium in drinking water.

Kopec AK, Kim S, Forgacs AL, Zacharewski TR, Proctor DM, Harris MA, Haws LC, Thompson CM.

Toxicol Appl Pharmacol. 2012 Feb 15;259(1):13-26. doi: 10.1016/j.taap.2011.11.012. Epub 2011 Dec 1.

28.

Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: implications for carcinogenic modes of action.

Thompson CM, Proctor DM, Suh M, Haws LC, Hébert CD, Mann JF, Shertzer HG, Hixon JG, Harris MA.

Toxicol Sci. 2012 Jan;125(1):79-90. doi: 10.1093/toxsci/kfr280. Epub 2011 Oct 19.

29.

Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium.

Thompson CM, Proctor DM, Haws LC, Hébert CD, Grimes SD, Shertzer HG, Kopec AK, Hixon JG, Zacharewski TR, Harris MA.

Toxicol Sci. 2011 Sep;123(1):58-70. doi: 10.1093/toxsci/kfr164. Epub 2011 Jun 28.

30.

Application of the U.S. EPA mode of action Framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium.

Thompson CM, Haws LC, Harris MA, Gatto NM, Proctor DM.

Toxicol Sci. 2011 Jan;119(1):20-40. doi: 10.1093/toxsci/kfq320. Epub 2010 Oct 14. Review.

31.

Reduction of a large fish tissue analyte database: identifying and assessing data specific to a remediation site for risk assessment application.

Tachovsky JA, Urban JD, Wikoff DS, Haws LC, Harris MA.

Chemosphere. 2010 Jul;80(5):481-8. doi: 10.1016/j.chemosphere.2010.04.072.

PMID:
20553933
32.

Assessment of human health risks posed by consumption of fish from the Lower Passaic River, New Jersey.

Urban JD, Tachovsky JA, Haws LC, Wikoff Staskal D, Harris MA.

Sci Total Environ. 2009 Dec 20;408(2):209-24. doi: 10.1016/j.scitotenv.2009.03.004. Epub 2009 Apr 23.

PMID:
19395001
33.

Levels of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls in southern Mississippi catfish and estimation of potential health risks.

Scott LL, Staskal DF, Williams ES, Luksemburg WJ, Urban JD, Nguyen LM, Haws LC, Birnbaum LS, Paustenbach DJ, Harris MA.

Chemosphere. 2009 Feb;74(7):1002-10. doi: 10.1016/j.chemosphere.2008.09.090. Epub 2008 Dec 23.

PMID:
19108868
34.

Analysis and integration of developmental neurotoxicity and ancillary data into risk assessment: a case study of dimethoate.

DeSesso JM, Watson RE, Keen CL, Hazelden KP, Haws LC, Li AA.

J Toxicol Environ Health A. 2009;72(2):94-109. doi: 10.1080/15287390802477452.

PMID:
19034799
35.

Assessment of polybrominated diphenyl ether exposures and health risks associated with consumption of southern Mississippi catfish.

Staskal DF, Scott LL, Haws LC, Luksemburg WJ, Birnbaum LS, Urban JD, Williams ES, Paustenbach DJ, Harris MA.

Environ Sci Technol. 2008 Sep 1;42(17):6755-61.

PMID:
18800560
36.

Assessment of potential human health risks posed by benzene in beverages.

Haws LC, Tachovsky JA, Williams ES, Scott LL, Paustenbach DJ, Harris MA.

J Food Sci. 2008 May;73(4):T33-41. doi: 10.1111/j.1750-3841.2008.00730.x.

PMID:
18460143
37.

Addendum to: Evaluation of PCDD/F and dioxin-like PCB serum concentration data from the 2001-2002 National Health and Nutrition Examination Survey of the United States population.

Scott LL, Unice KM, Scott P, Nguyen LM, Haws LC, Harris M, Paustenbach D.

J Expo Sci Environ Epidemiol. 2008 Sep;18(5):524-32. doi: 10.1038/jes.2008.10. Epub 2008 Mar 26.

PMID:
18368012
38.

Risk of gastrointestinal disease associated with exposure to pathogens in the sediments of the Lower Passaic River.

Donovan EP, Staskal DF, Unice KM, Roberts JD, Haws LC, Finley BL, Harris MA.

Appl Environ Microbiol. 2008 Feb;74(4):1004-18. Epub 2007 Dec 21.

39.

Evaluation of PCDD/F and dioxin-like PCB serum concentration data from the 2001-2002 National Health and Nutrition Examination Survey of the United States population.

Ferriby LL, Knutsen JS, Harris M, Unice KM, Scott P, Nony P, Haws LC, Paustenbach D.

J Expo Sci Environ Epidemiol. 2007 Jul;17(4):358-71. Epub 2006 Jul 5.

PMID:
16823400
40.

Development of a refined database of mammalian relative potency estimates for dioxin-like compounds.

Haws LC, Su SH, Harris M, Devito MJ, Walker NJ, Farland WH, Finley B, Birnbaum LS.

Toxicol Sci. 2006 Jan;89(1):4-30. Epub 2005 Aug 24. Review.

PMID:
16120753
41.
42.

Two approaches for assessing human safety of disperse blue 1.

Haws LC, Jackson BA, Turnbull D, Dressler WE.

Regul Toxicol Pharmacol. 1994 Feb;19(1):80-96.

PMID:
8159817
43.

Generally recognized as safe (GRAS) evaluation of 4-hexylresorcinol for use as a processing aid for prevention of melanosis in shrimp.

Frankos VH, Schmitt DF, Haws LC, McEvily AJ, Iyengar R, Miller SA, Munro IC, Clydesdale FM, Forbes AL, Sauer RM.

Regul Toxicol Pharmacol. 1991 Oct;14(2):202-12.

PMID:
1792354

Supplemental Content

Support Center